Commodore Capital Takes 9.9% Stake in Adicet Bio

TL;DR

**Commodore Capital just bought 9.9% of Adicet Bio, a big bullish signal!**

AI Summary

Commodore Capital LP, a Delaware-based investment firm, reported acquiring shared voting and dispositive power over 4,250,000 shares of Adicet Bio, Inc. common stock as of January 10, 2024. This significant stake represents 9.9% of Adicet Bio's outstanding shares, making Commodore Capital a major shareholder. This matters to investors because a large institutional investor taking a substantial position can signal confidence in the company's future, potentially influencing other investors and the stock price.

Why It Matters

A new large institutional investor, Commodore Capital LP, now owns 9.9% of Adicet Bio, which could be seen as a vote of confidence and potentially attract more investor interest.

Risk Assessment

Risk Level: low — This filing indicates a new large investor, which is generally a positive sign and does not inherently increase risk for current shareholders.

Analyst Insight

A smart investor would view this as a positive signal, potentially indicating institutional confidence in Adicet Bio. It might be worth researching Adicet Bio further, especially if considering buying or adding to an existing position, to understand what attracted Commodore Capital LP.

Key Numbers

• 4,250,000 — Shares Beneficially Owned (Represents the total number of Adicet Bio shares Commodore Capital LP now has shared voting and dispositive power over.)
• 9.9% — Ownership Percentage (Indicates Commodore Capital LP's significant stake in Adicet Bio, making them a major shareholder.)
• January 10, 2024 — Event Date (The specific date when Commodore Capital LP's ownership crossed the threshold requiring this SC 13G filing.)

Key Players & Entities

• Commodore Capital LP (company) — the reporting person acquiring shares
• Adicet Bio, Inc. (company) — the subject company whose shares were acquired
• Delaware (company) — place of organization for Commodore Capital LP
• January 10, 2024 (date) — date of event requiring the filing
• 4,250,000 (dollar_amount) — number of shares beneficially owned by Commodore Capital LP
• 9.9% (dollar_amount) — percentage of Adicet Bio's class of securities owned by Commodore Capital LP

Forward-Looking Statements

• Adicet Bio's stock price may see increased investor interest due to Commodore Capital's significant stake. (Adicet Bio, Inc.) — medium confidence, target: Q1 2024
• Commodore Capital LP may seek to engage with Adicet Bio's management on strategic initiatives given their substantial ownership. (Commodore Capital LP) — low confidence, target: Q2 2024

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti

Filing Documents

• formsc13g.htm (SC 13G) — 85KB
• ex1.htm (EX-1) — 8KB
• 0001493152-24-003061.txt ( ) — 95KB

for additional information

Item 4 for additional information. CUSIP No. 007002108 SCHEDULE 13G 1 NAME OF REPORTING PERSONS Commodore Capital Master LP 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 4,250,000* 7 SOLE DISPOSITIVE POWER 0 8 SHARED DISPOSITIVE POWER 4,250,000* 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,250,000* 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.8%* 12 TYPE OF REPORTING PERSON OO *See

for additional information

Item 4 for additional information. CUSIP No. 007002108 SCHEDULE 13G Item 1. (a) Name of Issuer Adicet Bio, Inc. (the “Issuer”) Item 1. (b) Address of Issuer’s Principal Executive Offices 200 Berkeley Street, 19th Floor, Boston, Massachusetts 02116 Item 2. (a, b, c) Names of Person Filing, Address of Principal Business Office, Citizenship: This report on Schedule 13G is being filed by Commodore Capital LP, a Delaware limited partnership (the “Firm”) and Commodore Capital Master LP, a Cayman Islands exempted limited partnership (“Commodore Master”). The address for the Firm and Commodore Master is: 444 Madison Avenue, Floor 35, New York, New York 10022. Item 2. (d) Title of Class of Securities Common Stock, par value $0.0001 per share (the “Common Stock”) Item 2. (e) CUSIP No.: 007002108 Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person filing is a: N/A CUSIP No. 007002108 SCHEDULE 13G Item 4. As reported in the cover pages to this report, the ownership information with respect to the Firm is as follows: (a) Amount Beneficially Owned: 4,250,000* (b) Percent of Class: 9.8%* (c) Number of Shares as to which such person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 4,250,000* (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: 4,250,000* As reported in the cover pages to this report, the ownership information with respect to Commodore Master is as follows: (a) Amount Beneficially Owned: 4,250,000* (b) Percent of Class: 9.8%* (c) Number of Shares as to which such person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 4,250,000* (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared po

View Full Filing

View this SC 13G filing on SEC EDGAR